Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

被引:153
作者
Moyle, G [1 ]
机构
[1] Chelsea & Westminster Hosp, London SW10 9NH, England
关键词
antiretroviral therapy; nucleoside analog; mitochondria; adverse effect; lipodystrophy; lactic acidosis;
D O I
10.1016/S0149-2918(00)80064-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: This article reviews the clinical manifestations of mitochondrial toxicity associated with the use of nucleoside analog reverse transcriptase inhibitors (NRTIs) and outlines strategies to manage these sequelae. Background: NRTIs are the key components of the antiretroviral combinations used in the management of patients infected with HIV. The available NRTIs differ in their convenience of administration, frequency of dosing, resistance profiles, and side-effect profiles. NRTIs act as competitive inhibitors of the RNA/DNA polymerase reverse transcriptase of HIV and cause chain termination in the growing viral DNA chain. Many of the important and treatment-limiting side effects of NRTIs may be related to the effect of these agents on human DNA polymerases, in particular, mitochondrial DNA polymerase gamma. Depletion of mitochondrial DNA during chronic NRTI therapy may lead to cellular respiratory dysfunction and generalized and tissue- and drug-specific toxicities, including myopathy, peripheral neuropathy, and lactic acidosis. Recently it has been proposed that the fat redistribution syndrome, or lipodystrophy, reported during chronic antiretroviral therapy is a manifestation of the differential impact of at least some NRTIs on peripheral and visceral adipocytes. Management of potential mitochondrial toxicity during NRTI therapy remains a challenge. A range of nutritional supplements, both as treatments and prophylaxes, have been proposed, and some have been investigated in vitro; no in vivo studies have yet been conducted. Methods: The information in this review was compiled using MEDLINE(R) and AIDSLINE(R) searches of the literature, including conference abstracts. Conclusions: At present, interruption of NRTI therapy or substitution of the probable causative agent with alternative NRTIs that appear to be better tolerated represents the mainstay of management for mitochondrial toxicity and its clinical manifestations.
引用
收藏
页码:911 / 936
页数:26
相关论文
共 138 条
  • [71] LOMBES A, 1989, REV NEUROL-FRANCE, V145, P671
  • [72] LONERGAN JT, 1999, CLIN INFECT DIS, V29, P1022
  • [73] Riboflavine and severe lactic acidosis
    Luzzati, R
    De Bravo, P
    Di Perri, G
    Luzzani, A
    Concia, E
    [J]. LANCET, 1999, 353 (9156) : 901 - 902
  • [74] Lipodystrophy in patients naive to HIV protease inhibitors
    Madge, S
    Kinloch-de-Loes, S
    Mercey, D
    Johnson, MA
    Weller, IVD
    [J]. AIDS, 1999, 13 (06) : 735 - 737
  • [75] MALLAL S, 1999, ANTIVIR THER S, V4, P28
  • [76] EFFECTS OF ANTIVIRAL NUCLEOSIDE ANALOGS ON HUMAN DNA-POLYMERASES AND MITOCHONDRIAL-DNA SYNTHESIS
    MARTIN, JL
    BROWN, CE
    MATTHEWSDAVIS, N
    REARDON, JE
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (12) : 2743 - 2749
  • [77] Metabolic abnormalities and use of HIV-1 protease inhibitors
    Martinez, E
    Gatell, J
    [J]. LANCET, 1998, 352 (9130) : 821 - 822
  • [78] Protease inhibitor-associated hyperinsulinaemia
    Martínez, E
    Casamitjana, R
    Conget, I
    Gatell, JM
    [J]. AIDS, 1998, 12 (15) : 2077 - 2079
  • [79] Metabolic abnormalities and body fat redistribution in HIV-1 infected patients:: the lipodystrophy syndrome
    Martínez, E
    Gatell, JM
    [J]. CURRENT OPINION IN INFECTIOUS DISEASES, 1999, 12 (01) : 13 - 19
  • [80] MARTINEZ E, 1999, 6 C RETR OPP INF JAN